Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
News from Hemp Roundtable today.
GREAT NEWS FROM TEXAS: This week, the Texas State Senate UNANIMOUSLY passed House Bill 1325, based on the Roundtable’s Model State Act. The bill would launch a hemp growth program – making Texas the 44th State in the USA -- and provide belt-and-suspenders protection for hemp products like CBD, with labeling and retailer registration requirements. The House is expected to concur with the Senate changes, meaning the bill could become law as early as today. Big thanks to all Hemp Supporters in the Lone Star State who had their voices heard!
GOOD NEWS FROM CALIFORNIA: Yesterday, the California Assembly’s Appropriations Committee UNANIMOUSLY passed AB 228, which would expressly permit the retail sale of hemp-derived CBD in foods and supplements, and also in topical applications. As you probably remember, last year, the California Department of Public Health issued guidance, inaccurately alleging that hemp-derived CBD is prohibited by law to be sold in retail stores in the state. The passage of AB 228 would redress the pronouncement which has cast a chill on legal commerce in popular products that promote health and wellness among California citizens, making clear that hemp and hemp-products are legal for retail sale. It is now onto the House floor, and we are pushing for a 2/3 vote to ensure its urgent application. If you live in California, please use our State Action Center today – urge your legislators to support AB 228. If not, please share with your friends and colleagues that do!
BLECCH NEWS FROM GEORGIA: Last week, Governor Brian Kemp signed House Bill 213 which makes Georgia the 42nd state to adopt a hemp growing program. The bill explicitly removed hemp-derived CBD from drug control. Unfortunately, this week, state Agriculture Commissioner Gary Black sent out this release that claims that because of the FDA’s guidance, CBD cannot be sold as a food additive or dietary supplement in the Peach State. Regular readers of this space know that the Roundtable strongly disagrees with this assessment – in our informed opinion, the FDA’s guidance is inaccurate, and it is neither final, nor legally binding. However, we anticipate a continued battle in the Georgia. Hemp Supporters, please stay tuned for our next strategy.
Traders must be loving this 30 minute chart over the last 10 days.
Has anyone tried reaching out to IR and asking why they can't give us an update. I'm pretty sure folks here have contacted them but as I remember, IR said they can't talk about it.
Is this correct?
How many here know that these two were at Nordic Naturals together?
Below is from a 2008 press release from Nordic Naturals
Dr. Douglas (a.k.a. Duffy) MacKay
Douglas MacKay, ND is a licensed Naturopathic Doctor who is committed to the advancement of natural and preventive medicine. Currently serving as Nordic Naturals Research Advisor, he facilitates the numerous ongoing human clinical trials using Nordic Natural products, and is developing research-based educational materials for professionals and consumers. Dr. MacKay also maintains a part-time practice, lectures regularly and is devoted to research and advocacy.
Stuart Tomc
With over twenty years experience in the field of Nutritional Medicine, Stuart Tomc is an authority on evidence-based dietary supplements. He is a respected consultant to the World Health Organization and integrative physicians worldwide having traveled the world as an educator and trainer for over 10 years. Stuart is adept at educating and delivering a powerful message on important health issues and currently serves as National Educator and Spokesperson for Nordic Naturals.
jefra: Let me add a little more to your thinking here.
Wall Street is paying attention!!
“Until recently, cannabis stocks were mostly ignored by most Wall Street firms. Few analysts covered or discussed cannabis stocks, and few investors paid attention to them at all. However, that dynamic has changed dramatically in the past year. Big-name firms like Jefferies, Cowen, Piper Jaffray have all initiated coverage of cannabis stocks. According to CNN, 13 different analysts now cover Canopy alone, up from eight analysts back in August. The more analysts cover cannabis stocks, the more comfortable investors will become and the more “buy” initiations will drive share prices higher.”
As is often the case, most retail (and definitely most traders) use a spotlight strategy to evaluate their investments. Only a few, such as yourself, jefra, use a floodlight. (how man hundreds if not 1000s of hours have you alone put into researching this company and space?) In this regard, few legitimate analysts cover OTC companies. Having a firm like Roth Capital Partners put out a buy rating validates our own “floodlight” DD and understanding of CVSI as a “growth play.” Just wait until we’re on Nasdaq when these firms actually give us “research reports” in addition to those buy ratings.
I’ll bet most retail investors aren’t aware of the process involved in an analysts buy rating.
Analysts research public financial statements, listen in on conference calls, TALK WITH MANAGEMENT and even talk with retailers and the customers of a company’s product (although I doubt Scott Fortune of Roth Capital went that far).
I do know that Scott Fortune has researched the Cannabis space extensively so his buy rating isn’t a manipulative sales tool.
His rating is the result of reasoned and objective analysis - he’s an experienced professional. It takes a lot of time and effort to analyze a company and to develop and maintain forecasts as you so well know. And, while different analysts may arrive at different conclusions, their ratings are efficient in summarizing their efforts. However, it’s also important to point out that a rating is one person's perspective, and it will not apply to every investor.
See here for an insightful article elucidating Mr. Fortune’s understanding of the Cannabis market: https://etfdailynews.com/2019/04/15/why-investors-should-be-enthusiastic-about-cannabis-stocks/
Should an investor interested in investing in CVSI react accordingly to new analyst's recommendations and adjust a position based on the analyst's rating alone? Of course not. The buy rating and/or research report and subsequent ratings should be used to complement an individual’s homework and strategy.
Just remember, ratings, like stock prices, can be manipulated by unscrupulous people, and have been for a long time. And just because a few analysts have been dishonest does not mean that all analysts are. Their assumptions may turn out to be wrong, but this does not mean that they did not do their best to provide investors with thorough and independent analysis. I trust Mr. Fortune is legit (and his last name certainly bodes well for my increased fortunes in CVSI!)
Many of us here did extensive homework years ago. And that homework never stopped. As the company executed their plan and grew, we continued to analyze all aspects of the company, their customers, the sector, the politics, etc.
We currently have two buy ratings. This is just the beginning!
https://www.tipranks.com/stocks/cvsi/price-target
Distinct products, distinct plants – that’s the only way’: Part 2 of a Q&A with CV Sciences exec Doug Mackay
https://hempindustrydaily.com/distinct-products-distinct-plants-thats-the-only-way-part-2-of-a-qa-with-cv-sciences-exec-doug-mackay/
As the hemp industry anticipates the U.S. Food and Drug Administration’s (FDA) first public hearing to start the process of regulating hemp extracts such as CBD in food, beverages and cosmetics, among others, a former dietary supplement executive now working with San Diego-based CBD manufacturer CV Sciences offers insight on regulatory compliance.
In Part 1 of Hemp Industry Daily‘s interview with CV Sciences’ senior vice president Douglas Mackay, he provided a perspective on what officials with both the FDA and the U.S. Department of Agriculture (USDA) will consider in the agencies’ regulatory oversight of hemp and CBD.
In Part 2, Mackay digs deeper on how CBD compares to FDA-regulated drugs and their competitive products, and what the hemp industry can learn from previous experience in regulating new food and dietary-supplement ingredients.
Can a drug company patent isolated CBD or restrict other companies from using it as an ingredient?
This isn’t a patent issue. This is a provision in the Food, Drug and Cosmetic Act, which says if an article has been investigated for clinical trials and those clinical trials have been made public, it cannot be introduced as a dietary supplement or food.
So, the question is, what is the article? The article that has been in clinical trials is 99.2% CBD.
If the supplement industry (puts forth the same article) as 99.2% CBD, the FDA’s going to say, “You lose, industry.” They’ve been down this road and gone to court on the same issues with pyridoxamine (vitamin B6) and monacolin K (lovastatin), and they know the solution.
But if the industry steps up and says, “Our article is hemp extract,” like CV Sciences’ product is, the FDA is going to say, “OK, explain to us why it’s safe.” And then that conversation will proceed.
Now, there is a provision in the Food, Drug and Cosmetic Act that says the FDA can issue an exception to the rule. The FDA can allow people to sell the prescription drug. However, to do that, they have to be absolutely sure that the ingredient is totally safe.
We know that isolated, highly purified CBD has some evidence that at certain levels starts to elevate liver enzymes. This isn’t fiber, this isn’t a vitamin – this is a potent bioactive compound that slows seizure activity at high levels, so it works in the central nervous system, which then brings up issues of drug/CBD.
These are things that the FDA will have to consider before it considers adding isolated CBD to foods.
How will this affect the different product areas, including foods and supplements?
We already have established swim lanes or regulatory categories with longstanding ways that plants are regulated.
Food, dietary supplements and drugs are different categories, and each has a different intended use. The FDA requires different levels of evidence for safety and effectiveness for each, and that’s what’s really going to help all of these distinct industries be successful.
Hemp farmers should be really advocating that the food and supplement space as the FDA and USDA make their rules is based on food/fiber hemp – and then drug-type (CBD hemp) growers can be feeding and supplying the prescription drug development.
But distinct products, distinct plants – that’s the only way.
If we blur the lines and we let growers play with different cultivars that are higher in CBD and lower in THC, and we have plants going into the supplement supply chain of varying levels of THC, it’s going to be a mess, and I don’t think very sustainable.
Do you think all CBD should be regulated as a drug?
No. I think highly purified, isolated CBD should be regulated as a drug, and it already is.
I think hemp extracts that contain CBD are absolutely appropriate in food and supplements if you do all of the appropriate work ahead of time that require selling in those categories.
Do you see any parallels between CBD and dietary supplements that have been approved?
There are actually two examples out there – stevia and red yeast rice.
About 15 years ago, everyone was freaking out about sugar and diabetes, so coming up with the next artificial sweetener was the gold rush.
Then, along came this plant that was 1,000 times sweeter than sugar. Stevia was a legal botanical – same as hemp – and it had already been in the supplement marketplace. But people started taking extracts, which would be a new ingredient, and adding it to drinks as a sweetener.
Everyone was excited about it. Investors had money flying around. Then the FDA started issuing warning letters saying stevia was not an approved food additive. Nobody had done the toxicology work to show that it could be added to food safely.
A big brand started doing the scientific work and came up with an ingredient called rebaudioside-A (reb-A).
They looked at stevia extract and realized there were some compounds in it that may not be safe, so they took them out. Then stevia was legal and in all the mainstream brands as a regular, natural, no-calorie sweetener.
The other example is red yeast rice, which speaks to the FDA exclusion where they’re saying you can’t add CBD or THC to food products because they are already approved drugs.
When you extract from red yeast rice, one of the compounds, monacolin K, is also the active ingredient of lovastatin, the cholesterol-lowering drug.
It’s the exact same scenario we have right now with hemp extracts that have all kinds of stuff in it, and yet one of those things is CBD and we have a prescription drug (Epidiolex) with CBD in it. That’s why the FDA is saying no to food and supplements currently.
Could the FDA regulate CBD in foods and supplements based on experience from these examples?
The question the FDA has to ask is when did the hemp extract – with all of its natural constituents and terpenes and cannabinoids – compete with a highly purified, isolated form of CBD?
One of the big things that people think the FDA will answer in this next series of meetings is whether it will allow CBD up to a certain level. They may or may not come to that conclusion.
The FDA could be a major disrupter in this market, and the major retailers are not going to touch anything if it’s outside of what the FDA considers compliant.
This interview has been edited for length and clarity.
Laura Drotleff can be reached at laurad@hempindustrydaily.com
Subscribe to our Newsletter
Categories: CBD Products & CBD Business News, Featured, Hemp Legalization & Regulatory News for Hemp Businesses
Ap17: you have to sign up in order to receive their ongoing updates. It’s the only way they can get there data.
LOL!
I only see my 130% gain and I only see the continuation of this trend toward $10. Intraday means absolutely nothing to the true longs.
Not sure about “something huge“ in addition to NASDAQ. Certainly we’d I’ll welcome continued positive news Let’s just get to NASDAQ first
CBD product development takes market consideration
https://www.naturalproductsinsider.com/herbs-botanicals/cbd-product-development-takes-market-consideration
According to early indicators, CBD is much more than a fad, penetrating grocery retailers and increasingly appearing in foods and beverages.
Perteet Spencer | Apr 23, 2019
Early indicators showed signs that cannabidiol (CBD) is much more than a fad. As consumers actively shift toward more natural remedies and legislation evolves in favor of cannabis, CBD and hemp, expansion potential is tremendous. Across the breadth of grocery retailers, about 95 percent of CBD’s US$48 million in sales are occurring in the natural channel, according to SPINSscan natural and specialty gourmet channels, conventional multi-outlet and convenience channels (powered by IRI), for the 52 weeks ending Nov. 4, 2018.
SPINS often refers to the natural and specialty gourmet channels as incubator or innovation channels, but this high concentration of early-adopter natural retailers may be an indicator of CBD’s potential to scale in mainstream channels over time. As consumer awareness, retail availability and the assortment of products expand, the landscape for CBD will look quite different over the next few years.
CBD’s already coming to market across several categories and formats, from body care to supplements to functional foods and beverages. It’s no surprise so many brands are attracted to the prospect of bringing CBD on board; the market opportunity so far has been impressive. SPINS tracked nearly 160 new introductions in the last year. While nearly 98 percent of sales volume currently comes from supplements, expansion beyond extracted oils is creating new opportunities for brands to enter the market. As an ingredient added to other formats, these extracted oils are versatile in any number of segments and formulations, offering many possibilities for expanded market presence. In fact, this year food and beverage offerings were the fastest-growing segment of CBD products—an early predictor of what’s to come.
Despite all the strong growth, brands entering the CBD market should consider if the ingredient aligns with its proposition and consumer base.
Get more information on CBD product development in INSIDER’s CBD Digital Magazine.
As principal of SPINS’ brand growth solutions, Perteet Spencer helps clients transform data into insights that fuel innovation.
Could be some short covering also driving this move as well
Good point! True dat!
I’m more interested in future growth and the resultant explosive earnings that will follow. Long and Patient!
Getting ready to retest the 52 week high set a few days ago.
So Berry was promoting and investing in PRED two years ago according to this video. There’s a whole lot more happening now than there was two years ago.
News out! CV Sciences’ PlusCBD Oil™ Used in First Study Examining Clinical Benefit of CBD for Patients with PTSD
May 14, 2019
Study Finds CBD Associated with PTSD Symptom Reduction in Adults with PTSD
LAS VEGAS, May 14, 2019 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, is pleased to announced that its industry-dominating PlusCBD Oil™ products were used in the first study to date examining the clinical benefit of CBD for the treatment of Post-Traumatic Stress Disorder (PTSD).
The study, published in The Journal of Alternative and Complementary Medicine in April 2019, examined the effect of oral CBD administration on symptoms of PTSD in a series of 11 adult patients at an outpatient psychiatry clinic. CV Sciences provided various PlusCBD Oil products for the study; delivery systems and usage were determined by patient and provider preference. The published study can be viewed at the following link: Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series. CV Sciences was not involved in the data collection, data interpretation, the preparation of the article, or the decision to submit for publication.
CBD was given on an open-label, flexible dosing regimen to patients diagnosed with PTSD by a mental health professional. Patients also received routine psychiatric care, including concurrent treatment with psychiatric medications and psychotherapy. The length of the study was eight weeks.
From the total sample of 11 patients, 10 experienced a decrease in PTSD symptom severity. The study concluded that administration of oral CBD in addition to routine psychiatric care was associated with PTSD symptom reduction in adults with PTSD. CBD also appeared to offer relief in a subset of patients who reported frequent nightmares as a symptom of their PTSD.
“We were impressed with the improvements seen in the subjects. These findings can help inform future clinical investigations, including double blind, placebo-controlled trials, to confirm the response to CBD that was observed in this study, “ says Scott Shannon, MD, principal investigator in the study.
“CV Sciences continued commitment to furthering scientific research allows us to better understand the benefits of CBD or a wide range of indications,” said Joseph Dowling, Chief Executive Officer. “After more than 80 years of prohibition, hemp CBD research has been severely hindered, but with the passage of the 2018 Farm Bill, we are beginning to understand the clinical benefits of CBD through scientific rigor. While we recognize that dietary supplements can’t be marketed for treating disease, we are pleased to support scientific progress by providing our PlusCBD Oil™ products to researchers and look forward to continued research on the clinical benefits of CBD for patients with PTSD and other indications.”
Thanks. I updated my messenge. I obviously was using outdated information
Update: Oops. Last message about only two Sprouts carrying our product is obviously outdated. My error. That’s exceptional news then
Yes, that’s exactly the right reference. I didn’t post it here because I didn’t want to draw attention to a relatively biased hit piece. The author was obsessed with finding questionable evidence to support his claims of a scam being perpetrated on unsuspecting individuals. (Granted, there are indeed scammers out there selling products with dead stem cells). I assumed the author was quite disgruntled because of the competitive advantage Predictive Biotech has.
Thanks for the insight.
Some long term smart holders here. I have an inquiry about the stem cell viability in their products. I have come across some reports that there aren't millions of stem cells in a number of cord cell vendors' products.
Still researching this subject.
Anyone have any updated lab tests supporting the claims made by PRED regarding millions of stem cells in their products.
I still haven't found third party verification of their claims.
TIA
No slight intended or desire for a pissing match oldman. it's always a good sign when we are as transparent as possible on an anonymous message board. Let's face it, folks do come here for insight, education and even to help with their decision making process,.
I'll definitely post my trades on the day they happen.
Cheers mate! Have a great weekend.
BTW, I do intend CDXC finally moves higher for you
oldman has been pumping CDXC for awhile now. they have nothing to do with PRED. He's been in that stock since 2014 and still waiting for it's BIG MOVE. No slight to you oldman. just the facts. just the facts!
oldman:
I doubt you know what you're talking about implying this ticker isn't a sure thing. Your CDXC ain't a sure thing either brother, so ya' better digest that pill as well. I know CDXC well. Have taken their TruNiagen for over a year. Love the product. but there ain't no guarantees they win the lawsuit. just conjecture at this point.
Looks like you been on that CDXC ROLLERCOASTER ride since 2014. Jeez! How's that profit-taking strategy working out for you>?
Will PRED uplist? I think so. but yeah, that's conjecture as well. I be much more confident in a double to triple with PRED right now by the end of summer or Fall given their pipeline and management and the space they're in than I would be with CDXC.
And I have traded CDXC successfully. Surprised you haven't followed your own advice with CDXC that you expound on here.
I'll stick with holding my PRED through $5 thank you very much.
I'll definitely remember to chat with you in 2-3 months to see how it goes.
I have multiple bids in 3.60, 3.50 and 3.40
Doesn’t look possible though. Bounced hard off 3.60
Look at the spreads. Up to .10 at times. Total manipulation on those 100 trades. Trying hard to lure weak hands into selling
I’ve been a trader at heart for a long time. I’ve changed my strategies with PRED. Although I did trade it from .85 to 2.20, I ended up taking an even larger position after that trade in the mid $2s. Im betting heavy on the uplist and a multi dollar spike on consecutive days. I will reevaluate along the way. $15 sell order is just a placecard for now.
Volume on the uptick speaks VOLUMES!!!
Many here were buying under a $1 and continued accumulating through the 2s. The friend who told me about Pred at .85 is still buying in this range. We aren’t even close to any major profit taking. My current limit sell order is $15. Won’t sell a share until after uplist and then will only peal off about 20%
Bear: Brilliant man! Thanks for saving it. I had plans to do reread to when I got home.
Did someone today mention Adam Feuerstein on this board or was it another board? I now can’t find the post. It was a brilliant insight into market dynamics as well as what happens when Alan decides to take down a good company.
Thought I had this troll un-glow on ignore. You have to be kidding with your rehash of this fake narrative. Ignored now!!
Educate yo self big boy!!
Man, where you folks been?? AH trades are settlements. Has absolutely nothing to do with a dump. Jeez!! OTC closing price is always the price at the close at 1:00
Just a reminder. This ticker has a minuscule 9 million share float.
On Nasdaq acceptance (right around the corner IMO), we could see a Multi-dollar gain over successive days.
This train is just leaving the platform IMO.
Of course, there are no guarantees, but this one, by all the fins and management team, looks to have very little downside risk.
Excellent point. Hadn't thought about that aspect. That's one metric to use in terms of an exit strategy. I'll just count the daily posts here and sell once the pumpers and dumpers are stampeding. Ha!
Bear raid! We'll only know if $3 is new support after it's been tested numerous times
haha - looks like I spoke too soon. Congrats to the day and swing traders. Players gotta do their Thang! Great buying Opp under $3. I'm out of ammo
I just don’t see this pulling back under $3 with the momentum going into earnings next week. Of course, I could be wrong and have been wrong many times. You gotta know there’s more positive news coming. Acquisition?? Partnership??